338 related articles for article (PubMed ID: 25398067)
1. HIV preexposure prophylaxis in the real world.
Daskalakis DC
Top Antivir Med; 2014; 22(4):670-5. PubMed ID: 25398067
[TBL] [Abstract][Full Text] [Related]
2. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.
Cohen SE; Vittinghoff E; Bacon O; Doblecki-Lewis S; Postle BS; Feaster DJ; Matheson T; Trainor N; Blue RW; Estrada Y; Coleman ME; Elion R; Castro JG; Chege W; Philip SS; Buchbinder S; Kolber MA; Liu AY
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):439-48. PubMed ID: 25501614
[TBL] [Abstract][Full Text] [Related]
3. HIV preexposure prophylaxis: new data and potential use.
Celum CL
Top Antivir Med; 2011 Dec; 19(5):181-5. PubMed ID: 22298887
[TBL] [Abstract][Full Text] [Related]
4. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
Sagaon-Teyssier L; Suzan-Monti M; Demoulin B; Capitant C; Lorente N; Préau M; Mora M; Rojas Castro D; Chidiac C; Chas J; Meyer L; Molina JM; Spire B;
AIDS Care; 2016; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
[TBL] [Abstract][Full Text] [Related]
5. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
Myers GM; Mayer KH
AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
[TBL] [Abstract][Full Text] [Related]
6. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
Marcus JL; Glidden DV; Mayer KH; Liu AY; Buchbinder SP; Amico KR; McMahan V; Kallas EG; Montoya-Herrera O; Pilotto J; Grant RM
PLoS One; 2013; 8(12):e81997. PubMed ID: 24367497
[TBL] [Abstract][Full Text] [Related]
7. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
[TBL] [Abstract][Full Text] [Related]
8. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
Li J; Dufrene SL; Okulicz JF
Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492
[TBL] [Abstract][Full Text] [Related]
9. Preexposure chemoprophylaxis for HIV prevention.
Underhill K
N Engl J Med; 2011 Apr; 364(14):1374; author reply 1374-5. PubMed ID: 21470023
[No Abstract] [Full Text] [Related]
10. Preexposure chemoprophylaxis for HIV prevention.
Pittrof R; Sauer U; French P
N Engl J Med; 2011 Apr; 364(14):1374; author reply 1374-5. PubMed ID: 21470022
[No Abstract] [Full Text] [Related]
11. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).
King HL; Keller SB; Giancola MA; Rodriguez DA; Chau JJ; Young JA; Little SJ; Smith DM
AIDS Behav; 2014 Sep; 18(9):1722-5. PubMed ID: 25017425
[TBL] [Abstract][Full Text] [Related]
12. Preexposure prophylaxis for the prevention of HIV transmission to women.
Aaron E; Cohan D
AIDS; 2013 Jan; 27(1):F1-5. PubMed ID: 22914582
[TBL] [Abstract][Full Text] [Related]
13. [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].
Boot J; Rump BO; Boucher CA; Op de Coul EL; van Agtmael MA; van de Vijver DA; Burger DM; Fanoy EB
Ned Tijdschr Geneeskd; 2013; 157(27):A6063. PubMed ID: 23838402
[TBL] [Abstract][Full Text] [Related]
14. Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
Baeten JM; Haberer JE; Liu AY; Sista N
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S122-9. PubMed ID: 23764623
[TBL] [Abstract][Full Text] [Related]
15. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
[TBL] [Abstract][Full Text] [Related]
16. Maximizing the Benefits of HIV Preexposure Prophylaxis.
Buchbinder SP
Top Antivir Med; 2018 Apr; 25(4):138-142. PubMed ID: 29689539
[TBL] [Abstract][Full Text] [Related]
17. Ethics and pre-exposure prophylaxis for HIV infection.
Sugarman J; Mayer KH
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S135-9. PubMed ID: 23764625
[TBL] [Abstract][Full Text] [Related]
18. Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2013 Jun; 62(23):463-5. PubMed ID: 23760186
[TBL] [Abstract][Full Text] [Related]
19. Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand.
Yang D; Chariyalertsak C; Wongthanee A; Kawichai S; Yotruean K; Saokhieo P; Guadamuz T; Suwanvanichkij V; Beyrer C; Chariyalertsak S
PLoS One; 2013; 8(10):e76650. PubMed ID: 24116132
[TBL] [Abstract][Full Text] [Related]
20. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
Krakower D; Mayer KH
Ann Intern Med; 2012 Oct; 157(7):490-7. PubMed ID: 22821365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
